社区痴呆患者药物相关问题患病率与风险因素的系统综述与Meta分析
该系统综述与Meta分析纳入22项研究(4项横断面研究、18项队列研究,样本量81至21795),评估社区痴呆患者药物相关问题(DRPs)的患病率及风险因素。任何不良药物事件(ADEs,含不良反应)的合并患病率为19.0%(95%CI 11.6%-27.7%),特定类型ADEs合并患病率为2.6%至10.2%,用药错误患病率为0.9%至41.3%。精神药物、多重用药和不适当用药增加DRPs风险,而用药管理支持为保护因素。
要点
- 社区痴呆患者任何ADEs合并患病率为19.0%(95%CI 11.6%-27.7%)。
- 精神药物、多重用药和不适当用药增加DRPs风险。
- 用药管理支持是DRPs的保护因素。
核心结论
- 社区痴呆患者总体DRPs患病率在纳入研究中差异很大。
- 特定药物、患者和用药管理因素与痴呆患者发生DRPs的风险相关,可指导临床识别高风险情形并实施缓解策略。
研究设计与样本
- 系统综述与Meta分析,检索Embase、Medline、PsycINFO、International Pharmaceutical Abstracts、Scopus和CINAHL六个数据库。
- 纳入22项研究:4项横断面研究和18项队列研究,参与者数量范围为81至21795。
- 研究对象为居住在社区的痴呆患者。
- 主要结局为药物不良反应(ADRs)、不良药物事件(ADEs)和用药错误(MEs)。
主要发现
- 任何ADEs(包括ADRs)的合并患病率为19.0%(95%CI 11.6%-27.7%)。
- 特定类型ADEs的合并患病率范围为2.6%至10.2%。
- 用药错误(MEs)的患病率范围为0.9%至41.3%。
- 精神药物、多重用药和不适当用药与DRPs风险增加相关。
- 用药管理支持是DRPs的保护因素。
关键数值与推荐
- 任何ADEs(包括ADRs)合并患病率:19.0%(95%CI 11.6%-27.7%)。
- 特定类型ADEs合并患病率范围:2.6%至10.2%。
- 用药错误(MEs)患病率范围:0.9%至41.3%。
临床怎么用
- 临床应关注社区痴呆患者中使用精神药物、多重用药和不适当用药的高风险情形。
- 对社区痴呆患者提供用药管理支持可能有助于降低DRPs风险。
- 临床可依据上述风险因素识别高风险患者并实施适合的缓解策略。
局限性
- 纳入研究中总体DRPs患病率高度变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The aims of this systematic review were to identify the prevalence and risk factors associated with drug-related problems (DRPs) in people living with dementia in the community. DESIGN: A systematic review and meta-analysis. SETTING AND PARTICIPANTS: People with dementia living in the community. METHODS: Six databases (Embase, Medline, PsycINFO, International Pharmaceutical Abstracts, Scopus, and CINAHL) were searched using a combination of keywords and Medical Subject Heading (MeSH) terms with 4 concepts: dementia, older adults, DRPs, and community-dwelling. Primary outcomes were adverse drug reactions (ADRs), adverse drug events (ADEs), and medication errors (MEs). RESULTS: There were 22 studies included: 4 cross-sectional studies and 18 cohort studies. The number of participants in these studies ranged from 81 to 21,795. The pooled prevalence for any ADEs, including ADRs, in people living with dementia was 19.0% (95% CI 11.6%-27.7%), whereas the pooled prevalence for specific types of ADEs ranged from 2.6% to 10.2%. Furthermore, the prevalence of MEs ranged from 0.9% to 41.3%. Psychotropic medications, polypharmacy, and inappropriate medications contributed to an increased risk of experiencing DRPs, whereas support with medication management was a protective factor. CONCLUSIONS AND IMPLICATIONS: The prevalence of overall DRPs experienced by people with dementia was highly variable in included studies. Awareness that certain medication, patient, and medication management factors are associated with the risk of people with dementia experiencing DRPs may guide clinicians to identify high-risk situations and implement suitable mitigation strategies.
引用
- Lau ECY, Wojt I, Jeon YH, et al. Prevalence and Risk Factors for Drug-Related Problems in People With Dementia Living in the Community: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2022. PMID: 35276086. doi:10.1016/j.jamda.2022.01.083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。